首页> 美国卫生研究院文献>Frontiers in Oncology >Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature
【2h】

Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature

机译:外显子19-del-EGFR突变型肺腺癌同时进行阿法替尼和全脑放疗:一例病例并文献复习

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Leptomeningeal metastases (LM) are found in approximately 3.8% of non-small cell lung cancer cases with an increased incidence in adenocarcinoma, and approximately one-third of patients will present with concomitant brain metastases. We report the case of a 50-year-old male patient with stage IV exon 19-del-EGFR mutant lung adenocarcinoma who progressed on second-generation TKI therapy with manifestation of symptomatic simultaneous diffuse brain and LM. Whole-brain radiotherapy with concurrent afatinib resulted in an almost complete regression of neurological symptoms as well as good, durable radiological response. Furthermore, treatment was well tolerated with no relevant adverse effects.
机译:在约3.8%的非小细胞肺癌病例中发现了软脑膜转移瘤(LM),其在腺癌中的发病率增加,并且大约三分之一的患者会伴有脑转移。我们报道了一名50岁男性患者,该患者患有IV期外显子19-del-EGFR突变型肺腺癌,其在第二代TKI治疗上进展,同时表现为症状性弥漫性脑和LM。并发阿法替尼的全脑放疗导致神经症状几乎完全消退,并且放射学反应良好,持久。此外,治疗耐受性良好,无相关不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号